相关实验视频
Updated: Jun 7, 2025

04:39
Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
Published on: March 17, 2023
1.6K
系统性免疫炎症指数和系统性炎症反应指数预测差异化甲状腺癌对放射性治疗的反应
Yan Wang1,2, Junshun Chang1, Ben Hu3
1Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030001, People's Republic of China.
Journal of inflammation research
|November 14, 2024
概括
系统性免疫炎症指数和系统性炎症反应指数可以预测差异化甲状腺癌患者的放射性治疗反应. 这些炎症标志物可能有助于临床决定治疗有效性.
科学领域:
- 在瘤学瘤学.
- 核医学就是核医学.
- 生物标志物 生物标志物
背景情况:
- 差异化甲状腺癌 (DTC) 治疗通常涉及放射性 (RAI) 治疗.
- 预测RAI治疗的反应对于优化患者的治疗结果至关重要.
- 新的炎症标志物可能为RAI治疗成功提供预测价值.
研究的目的:
- 评估系统性免疫炎症指数 (SII) 和系统性炎症反应指数 (SRI) 在预测DTC患者RAI治疗反应方面的临床实用性.
- 评估治疗前SII和SRI水平之间的关联,以及实现RAI治疗优异反应 (ER) 的可能性.
主要方法:
- 对406名接受初始RAI治疗的DTC患者的回顾性分析.
- 在治疗前从周围血液细胞计数计算SII和SRI.
- 多变量后勤回归和ROC曲线分析以确定预测准确度.
主要成果:
- 与ER组相比,RAI反应低于最佳的患者 (非ER组) 呈现出明显更高的治疗前SII和SRI水平 (p < 0.001).
- 无论是SII (AUC=0.692) 和SRI (AUC=0.664) 都表现出对RAI治疗反应的显著预测能力.
- 确定了SII (668.91) 和SRI (0.47) 的最佳切割值,以及相关的灵敏度和特异性.
结论:
- 在DTC中,SII和SRI是预测RAI治疗反应的潜在生物标志物.
- 这些炎症指数可以作为临床医生在管理DTC患者时的宝贵辅助工具.
- 需要进一步的研究来证实SII和SRI在临床环境中的实际应用.
相关概念视频
Synthesis and Regulation of Thyroid Hormones
4.2K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.2K
Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117

